Today Moderna published the data on Phase 1 clinical safety trials on 45 adults. It looks like two doses per season will be the established dose approximately one month apart . The 100 microgram dose appears to have elicited very good neutralizing antibody response with minimal immediate side effects. Phase 2 studies looking at 600 adults will likely be reported on in the next 4-6 weeks. The company is initiating Phase 3 trials on 30,000 individuals after July 27, 2020. This will be the most critical phase in order to see how the vaccine protects in actual exposed populations during an outbreak. The post Phase 3 observation period is expected to go on for several months in order to ensure safety as discussed previously. At that point if the current progress continues , the FDA will consider approval. Most indicators according to this study are that immunogenicity looks positive. The FDA is being very cautious before giving any indications of approval. Other vaccine candidates should be reporting on Phase 1 shortly. Will follow closely as the safety and efficacy trials continue. Phase 1 New England Journal of Medicine Study